Portal Dosimetry Research Articles

VMAT TBI Technique Based on Automated Treatment Planning

<h3>Purpose/Objective(s)</h3> In this work, we describe the technical aspects of our VMAT TBI technique, compare it to other VMAT TBI techniques, and share our initial experience. <h3>Materials/Methods</h3> From 2019 to 2021, 35 patients were treated with VMAT TBI at our institution. Treatment planning was performed using in-house developed automated planning scripts. Organ sparing depended on the regimen: myeloablative (lungs, kidneys, and lenses); non-myeloablative (lungs, kidneys, lenses, gonads, brain, and thyroid). Quality assurance was performed using EPID portal dosimetry and patient quality assurance platform. Robustness was evaluated for the first ten patients by performing local and global isocenter shifts of 5 mm. Treatment was delivered using IGRT for every isocenter and every fraction. In- vivo measurements were performed on the matchline between the VMAT and AP/PA fields and on the testes for the first fraction. <h3>Results</h3> The lungs, lungs-1cm, and kidneys D_mean were consistently spared to 57.6<i>±</i>4.4%, 40.7<i>±</i>5.5%, and 70.0<i>±</i>9.9% of the prescription dose, respectively. Gonadal sparing (D_mean=0.69<i>±</i>0.13 Gy) was achieved for all patients with benign disease. The average PTV D_1cc was 120.7<i>±</i>6.4% for all patients. The average Gamma passing rate for the VMAT plans was 98.1<i>±</i>1.6% (criteria of 3%/2mm). Minimal differences were observed between Mobius3D- and EclipseAAA-calculated PTV D_mean (0.0<i>±</i>0.3%) and lungs D_mean (-2.5<i>±</i>1.2%). Robustness evaluation showed that the PTV D_max and lungs D_mean are insensitive to small positioning deviations between the VMAT isocenters (1.1<i>±</i>2.4% and 1.2<i>±</i>1.0%, respectively). The average matchline dose measurement indicated patient setup was reproducible (96.1<i>±</i>4.5% relative to prescription dose). Treatment time, including patient setup and beam-on, was 47.5±9.5 min. <h3>Conclusion</h3> VMAT TBI is a modern alternative to conventional 2D TBI treatment. Together with publicly shared autoplanning scripts, our technique may provide the gateway for wider adaptation of this technology and the possibility of multi-institutional studies in the cooperative group setting.

Transit dosimetry of stereotactic body radiotherapy treatments with electronic portal dosimetry device in patient with spinal implant.

In recent years, the use of the Electronic Portal Imaging Device (EPID) as an in vivo dosimeter has become widespread. However, reports of EPID for stereotactic body radiotherapy (SBRT) applications is scarce. There is no data on this topic especially when there are high-density materials in the radiation field. In this study, we aimed to investigate the dose distributions of SBRT treatment plans in patients with spinal implants by transit EPID dosimetry. Implants were inserted in phantoms that mimic the vertebrae, and VMAT plans were created on the phantoms to deliver 16Gy radiation doses to the target in 1 fraction. Transit EPID measurements were performed for each irradiation. The results were compared with the treatment planning system using the gamma analysis method. According to the gamma analysis results, while the non-implant model met the acceptance criteria with a rate of 95.4%, the implanted models did not pass the test with results between the rates of 70% to 73%. In addition, while the dose difference in the isocenter was 1.3% for the non-implanted model, this difference was observed to be between 7 and 8% in the implanted models. Our study revealed that EPID can be used as transit dosimetry for the VMAT-SBRT applications. However, unacceptable dose differences were obtained by transit EPID dosimetry in the VMAT-SBRT applications of patients with an implant. In the treatment of such patients, alternative treatment methods should be preferred in which the interaction of the implants with radiation can be prevented.

Portal dosimetry correction method for validation of single isocenter VMAT plans for multiple brain metastases.

Portal dosimetry is one option for verification of volumetric‐modulated arc therapy (VMAT) planning for multiple brain metastases. However, due to the changing response of the portal imager with photon beam energy, the dose transmitted through closed multileaf collimator (MLC) leaves or narrow MLC gaps may be underestimated by the imager.We present a simple method for correcting for these effects that may be implemented within the Eclipse treatment planning system. We recalculated the predicted portal dose with and without this correction for 20 multiple brain met VMAT plans. Before the correction, 3/20 composite plan fields passed our standard quality assurance (QA) criteria (54/80 individual fields); the average gamma passing rate for the composite plans was 76.9 ± 16.6%, and the average gamma value across the composite plans was 0.67 ± 0.23. After correction, 20/20 composite plan fields passed the QA criteria (80/80 individual fields); the average gamma passing rate for composite plans was 99.2 ± 1.4%, the average gamma value across the composite plans was 0.33 ± 0.90. A measure of plan complexity, the average leaf pair opening could be correlated to the gamma analysis results for the uncorrected plans but not for the corrected plans.

Clinical performance evaluation of O-Ring Halcyon Linac: A real-world study.

BACKGROUNDRadiation therapy, especially the development of linear accelerators, plays a key role in cancer management. The fast-rotating coplanar O-ring Halcyon Linac has demonstrated many advantages. The previous literature has mainly focused on the machine parameters and plan quality of Halcyon, with a lack of relevant research on its clinical application.AIMTo evaluate the clinical performance of the O-ring Halcyon treatment system in a real-world application setting.METHODSData from sixty-one patients who were treated with the Halcyon system throughout the entire radiotherapy process in Peking Union Medical College Hospital between August 2019 and September 2020 were retrospectively reviewed. We evaluated the target tumour response to radiotherapy and irradiation toxicity from 1 to 3 mo after treatment. Dosimetric verification of Halcyon plans was performed using a quality assurance procedure, including portal dosimetry, ArcCHECK and point dose measurements for verification of the system delivery accuracy.RESULTSOf the 61 patients in the five groups, 16, 12, 7 and 26 patients had complete response, partial response, progressive disease and stable disease, respectively. No increase in the irradiated target tumour volume was observed when separately evaluating the local response. Regarding irradiation toxicity, no radiation-induced deaths were observed. Thirty-eight percent (23/61 patients) had no radiation toxicity after radiotherapy, 56% (34/61 patients) experienced radiation toxicity that resolved after treatment, and 6% (4/61 patients) had irreversible adverse reactions. The average gamma passing rates with a 2% dose difference and 2-mm distance to agreement for IMRT/VMAT/SRT plans were ArcCHECK at 96.4% and portal dosimetry at 96.7%, respectively. All of the validated clinical plans were within 3% for point dose measurements, and Halcyon’s ArcCHECK demonstrated a high pass rate of 99.1% ± 1.1% for clinical gamma passing criteria of 3%/3 mm.CONCLUSIONThe O-ring Halcyon Linac could achieve a better therapeutic effect on the target volume by providing accurate treatment delivery plans with tolerable irradiation toxicity.

Investigation on the impact of the leaf trailing effect using the Halcyon integrated platform system.

The double-stacked design of the Halcyon multileaf collimator (MLC) presents new challenges for treatment planning systems (TPSs). The leaf trailing effect has recently been described as the result of the interplay between the fluence transmitted through the leaf tip ends of each MLC layer. This effect makes the dosimetric leaf gap (DLG) dependent on the distance between the leaves of different layers (trailing distance) and is not adequately modeled by the Eclipse TPS. The purpose of our study was to investigate and report the dose discrepancies produced by these limitations in clinical plans and to explore how these discrepancies can be mitigated and avoided. The integrated platform with the Halcyon v2 system, Eclipse and Aria v15.6, was used. The dose discrepancies were obtained with electronic portal imaging device (EPID) images and the portal dosimetry software and validated using radiochromic film dosimetry. The results for the AIDA commissioning test and for nine selected clinical beams with the sliding window intensity modulated radiotherapy (dIMRT) technique were thoroughly analyzed and presented. First, the digital imaging and communications in medicine radiotherapy (DICOM RT) plans were exported and the fluences were computed using different leaf tip models, and then were compared. Second, the detailed characteristics of the corresponding leaf sequences were investigated. Finally, modified DICOM RT plans were created in which the noncollimating (backup) leaves were retracted 2mm to increase the leaf trailing distance, the modified plans were imported back into the TPS and the measurements were repeated. Dedicated in-house tools were developed in Python to carry out allanalyses. Dose discrepancies greater than 10% and regions of gamma failure were found in both the AIDA test and clinical beams using static-gantry dIMRT. Fluence analysis highlighted that the discrepancies were due to limitations in the MLC model implemented in the TPS. Analysis of leaf sequences indicated that regions of failure were associated with very low leaf speeds and virtually motionless leaves within the beam aperture. Some of these discrepancies were mitigated by increasing the trailing distance of the noncollimating leaves without affecting the beam aperture, but this strategy was not possible in regions where the leaves from both layers actively defined the beamaperture. Current limitations of the MLC model in Eclipse produced discrepancies between calculated and delivered doses in clinical beams that caused plan-specific quality assurance failures and interruptions in the clinical workflow. Careful evaluation of the clinical plans produced by Eclipse for the Halcyon is recommended, especially for static gantry dIMRT treatments. Some characteristics of leaf sequences are problematic and should be avoided in clinical plans and, in general, a better leaf tip model is needed. This is particularly important in adaptive radiotherapy treatments, where the accuracy and reliability of TPS dose calculations are of the utmostimportance.

Clinical rationale for in vivo portal dosimetry in magnetic resonance guided online adaptive radiotherapy.

In magnetic resonance guided online adaptive radiotherapy, the patient model used for plan adaptation and dose calculation is created online under stringent time constraints. This study investigated the ability of in vivo portal dosimetry to detect deviations between the online patient model used for plan adaptation and the actual anatomy of the patient during delivery. Portal images acquired during treatment were used to reconstruct the delivered dose corresponding to online adapted plans of 42 prostate and 20 rectal cancer patients. The reconstructed dose distributions were compared with the dose distributions calculated online by the treatment planning system by γ-analysis and by the difference in median dose to the high-dose volume. Out of 245 prostate and 145 rectal cancer adapted plans, deviations were detected in 5 prostate and in 17 rectal adapted plans corresponding to 3 prostate and 6 rectal patients, respectively. For all but one of the alerts, deviations were explained due to discrepancies observed between the patient model used for plan adaptation and online magnetic resonance images. A single workflow incident in which the supporting arm of the anterior receive coil was accidentally moved in the treatment field was also detected. There is need for independent end-to-end checks in magnetic resonance guided online adaptive workflows including the verification of the online patient model. In vivo portal dosimetry can be used for such purpose as it can detect both patient related deviations and workflow incidents.

Improvement of IMRT QA prediction using imaging-based neural architecture search.

Machine learning (ML) has been used to predict the gamma passing rate (GPR) of intensity-modulated radiation therapy (IMRT) QA results. In this work, we applied a novel neural architecture search to automatically tune and search for the best deep neural networks instead of using hand-designed deep learning architectures. One hundred and eighty-two IMRT plans were created and delivered with portal dosimetry. A total of 1497 fields for multiple treatment sites were delivered and measured by portal imagers. Gamma criteria of 2%/2mm with a 5% threshold were used. Fluence maps calculated for each plan were used as inputs to a convolution neural network (CNN). Auto-Keras was implemented to search for the best CNN architecture for fluence image regression. The network morphism was adopted in the searching process, in which the base models were ResNet and DenseNet. The performance of this CNN approach was compared with tree-based ML models previously developed for this application, using the same dataset. The deep-learning-based approach had 98.3% of predictions within 3% of the measured 2%/2-mm GPRs with a maximum error of 3.1% and a mean absolute error of less than 1%. Our results show that this novel architecture search approach achieves comparable performance to the machine-learning-based approaches with handcrafted features. We implemented a novel CNN model using imaging-based neural architecture for IMRT QA prediction. The imaging-based deep-learning method does not require a manual extraction of relevant features and is able to automatically select the best network architecture.

PD-0805 3D Portal Dosimetry for extreme hypofraction: pre-treatment and in vivo verification

PD-0805 3D Portal Dosimetry for extreme hypofraction: pre-treatment and in vivo verification

Dosimetric Importance of Implementing Jaw Tracking Technique in Radiotherapy Treatment Plan Execution.

Objective: To study the dosimetric importance of Jaw tracking technique in reducing the doses to organs at risk (OAR) while achieving the optimal dose coverage for the target. Methods:We retrospectively selected ten Glioblastoma cases and for each patient, two plans were created namely Static Jaw Technique Dynamic Intensity Modulated Radiotherapy plan and Jaw Tracking Technique D-IMRT plan with 6 MV for Varian Truebeam™ STx machine using Eclipse Treatment planning system. Both plans were analyzed and compared based on various dosimetric parameters for Planning Target Volume (PTV) and OARs. The dose agreement between the Portal dose image prediction and the portal dosimetry measurement was also analysed using gamma analysis criteria of 3%/3mm, 2%/2mm and 1%/1mm of dose distance/distance-to-agreement. Results: The dosimetric parameters evaluated for both plans showed that most of the parameters gave significant P values, where D50% of PTV showed a mean difference (Δ) of 0.45 with significant P value, 0.0104. Similarly mean dose, D2%, D98%, D80% to PTV, Conformity Index and Conformation number showed Δ values of 0.45, 0.51, 0.41, 0.40, 0.02 and 0.01 with their significant P values as 0.0138, 0.0172, 0.0313, 0.0466, 0.0279, 0.0561 respectively. The Δ values and significant P values obtained among OARs are 0.54;0.0224 for brainstem, 0.54;0.0017 for RT optic nerve, 0.52;0.0001 for LT optic nerve, 0.59;0.0040 for optic chiasm and for the healthy tissues it showed the values with their mean dose, V5 and V30 parameters as 0.19;0.0115, 0.59;0.0067 and 0.25;0.0125 respectively. The JTT plans showed better passing results of gamma analysis criteria when compared to SJT plans. Conclusion: The findings in the studies emphasize the importance of using JTT technique in the radiotherapy treatment plans as it lowers the risk of acute or late toxicity and secondary radiogenic cancers in patients by reducing the OAR doses and achieves better tumor control.

A recurrent neural network for rapid detection of delivery errors during real-time portal dosimetry.

Real-time portal dosimetry compares measured images with predicted images to detect delivery errors as the radiotherapy treatment proceeds. This work aimed to investigate the performance of a recurrent neural network for processing image metrics so as to detect delivery errors as early as possible in the treatment. Volumetric modulated arc therapy (VMAT) plans of six prostate patients were used to generate sequences of predicted portal images. Errors were introduced into the treatment plans and the modified plans were delivered to a water-equivalent phantom. Four different metrics were used to detect errors. These metrics were applied to a threshold-based method to detect the errors as soon as possible during the delivery, and also to a recurrent neural network consisting of four layers. A leave-two-out approach was used to set thresholds and train the neural network then test the resulting systems. When using a combination of metrics in conjunction with optimal thresholds, the median segment index at which the errors were detected was 107 out of 180. When using the neural network, the median segment index for error detection was 66 out of 180, with no false positives. The neural network reduced the rate of false negative results from 0.36 to 0.24. The recurrent neural network allowed the detection of errors around 30% earlier than when using conventional threshold techniques. By appropriate training of the network, false positive alerts could be prevented, thereby avoiding unnecessary disruption to the patient workflow.

Extending in aqua portal dosimetry with dose inhomogeneity conversion maps for accurate patient dose reconstruction in external beam radiotherapy.

Background and purposeIn aqua dosimetry with electronic portal imaging devices (EPIDs) allows for dosimetric treatment verification in external beam radiotherapy by comparing EPID-reconstructed dose distributions (EPID_IA) with dose distributions calculated with the treatment planning system in water-equivalent geometries. The main drawback of the method is the inability to estimate the dose delivered to the patient. In this study, an extension to the method is presented to allow for patient dose reconstruction in the presence of inhomogeneities.Materials and methodsEPID_IA dose distributions were converted into patient dose distributions (EPID_IA_MC) by applying a 3D dose inhomogeneity conversion, defined as the ratio between patient and water-filled patient dose distributions computed using Monte Carlo calculations. EPID_IA_MC was evaluated against dose distributions calculated with a collapsed cone convolution superposition (CCCS) algorithm and with a GPU‐based Monte Carlo dose calculation platform (GPUMCD) using non-transit EPID measurements of 25 plans. In vivo EPID measurements of 20 plans were also analyzed.ResultsIn the evaluation of EPID_IA_MC, the average γ-mean values (2% local/2mm, 50% isodose volume) were 0.70 ± 0.14 (1SD) and 0.66 ± 0.10 (1SD) against CCCS and GPUMCD, respectively. Percentage differences in median dose to the planning target volume were within 3.9% and 2.7%, respectively. The number of in vivo dosimetric alerts with EPID_IA_MC was comparable to EPID_IA.ConclusionsEPID_IA_MC accommodates accurate patient dose reconstruction for treatment disease sites with significant tissue inhomogeneities within a simple EPID-based direct dose back-projection algorithm, and helps to improve the clinical interpretation of both pre-treatment and in vivo dosimetry results.

The Stanford Volumetric Modulated Arc Therapy Total Body Irradiation Technique

PurposeIn this article, we describe the technical aspects of the Stanford volumetric modulated arc therapy (VMAT) total body irradiation (TBI) technique, compare it with other VMAT-TBI techniques, and share our initial experience. Methods and MaterialsFrom September 2019 to August 2021, 35 patients were treated with VMAT-TBI at our institution. Treatment planning was performed using in-house developed automated planning scripts. Organ sparing depended on the regimen: myeloablative (lungs, kidneys, and lenses) and nonmyeloablative with benign disease (lungs, kidneys, lenses, gonads, brain, and thyroid). Quality assurance was performed using electronic portal imaging device portal dosimetry and Mobius3D. Robustness was evaluated for the first 10 patients by performing local and global isocenter shifts of 5 mm. Treatment was delivered using image-guided radiation therapy for every isocenter and every fraction. In vivo measurements were performed on the match line between the VMAT and anterior-posterior/posterior-anterior fields and on the testes for the first fraction. ResultsThe lungs, lungs – 1 cm, and kidneys Dmean were consistently spared to 57.6% ± 4.4%, 40.7% ± 5.5%, and 70.0% ± 9.9% of the prescription dose, respectively. Gonadal sparing (Dmean = 0.69 ± 0.13 Gy) was performed for all patients with benign disease. The average planning target volume (PTV) maximum dose to 1 cubic centimeter (D1cc) was 120.7% ± 6.4% for all patients. The average Gamma passing rate for the VMAT plans was 98.1% ± 1.6% (criterion of 3%/2 mm). Minimal differences were observed between Mobius3D- and Eclipse AAA-calculated PTV Dmean (0.0% ± 0.3%) and lungs Dmean (–2.5% ± 1.2%). Robustness evaluation showed that the PTV Dmax and lungs Dmean were insensitive to small positioning deviations between the VMAT isocenters (1.1% ± 2.4% and 1.2% ± 1.0%, respectively). The average match-line dose measurement indicated patient setup was reproducible (96.1% ± 4.5% relative to prescription dose). Treatment time, including patient setup and beam-on, was 47.5 ± 9.5 min. ConclusionsThe Stanford VMAT-TBI technique, from simulation to treatment delivery, was presented and compared with other VMAT-TBI techniques. Together with publicly shared autoplanning scripts, our technique may provide the gateway for wider adaptation of this technology and the possibility of multi-institutional studies in the cooperative group setting.

A transit portal dosimetry method for respiratory gating quality assurance with a dynamic 3D printed tumor phantom.

BackgroundsRespiratory gating is one of the motion management techniques that is used to deliver radiation dose to a tumor at a specific position under free breathing. However, due to the dynamic feedback process of this approach, regular equipment quality assurance (QA) and patient‐specific QA checks need to be performed. This work proposes a new QA methodology using electronic portal imaging detector (EPID) to determine the target localization accuracy of phase gating.MethodsQA tools comprising 3D printed spherical tumor phantoms, programmable stages, and an EPID detector are characterized and assembled. Algorithms for predicting portal dose (PD) through moving phantoms are developed and verified using gamma analysis for two spherical tumor phantoms (2 cm and 4 cm), two different 6 MV volumetric modulated arc therapy plans, and two different gating windows (30%–70% and 40%–60%). Comparison between the two gating windows is then performed using the Wilcoxon signed‐rank test. An optimizer routine, which is used to determine the optimal window, based on maximal gamma passing rate (GPR), was applied to an actual breathing curve and breathing plan. This was done to ascertain if our method yielded a similar result with the actual gating window.ResultsHigh GPRs of more than 97% and 91% were observed when comparing the predicted PD with the measured PD in moving phantom at 2 mm/2% and 1 mm/1% levels, respectively. Analysis of gamma heatmaps shows an excellent agreement with the tumor phantom.The GPR of 40%–60% PD was significantly lower than that of the 30%–70% PD at the 1 mm/1% level (p = 0.0064). At the 2 mm/2% level, no significant differences were observed. The optimizer routine could accurately predict the center of the gating window to within a 10% range.ConclusionWe have successfully performed and verified a new method for QA with the use of a moving phantom with EPID for phase gating with real‐time position management.

Sensitivity of Three Patient-Specific Quality Assurance Systems to MLC Aperture Errors With Volumetric Modulated Arc Therapy.

Purpose: To compare the sensitivity of ArcCHECK (AC), portal dosimetry (PD), and an in-house logfile-based system (LF) to multileaf collimators (MLC) aperture errors and the ability to identify these errors. Methods and Materials: For 12 retrospective original head and neck volumetric modulated arc therapy (VMAT) plans, MLC aperture errors of ± 0.4mm, ± 1.2mm, ± 2mm, and ± 3mm were introduced for each plan, resulting in 96 plans with errors. AC, PD, and LF were used for the gamma evaluation at 3%/3mm, 3%/2mm, and 2%/2mm criteria. Gradient analysis was used to evaluate the sensitivity to MLC aperture errors. The area under the curve (AUC) obtained from the receiver operating characteristic (ROC) curve was used to evaluate the ability to identify MLC aperture errors and dose errors, and the optimal cut-off value to identify the error was obtained. Results: The gamma pass rate (%GP) of LF had the smallest descent gradient as the MLC error increases in any case. The descent gradient of PD was larger than AC, except for the case at the 2%/2mm criteria. For the 3%/3mm criteria, the MLC aperture errors that can be perfectly identified by AC, PD, and LF were ± 3mm, ± 2mm, and ± 1.2mm, respectively, and the average percent dose error (%DEs) of dose metrics in targets that can be perfectly identified were 4% to 5%, 3% to 4%, and 2% to 3%, respectively. For the 3%/2mm criteria, the errors that AC, PD, and LF can perfectly identify were the same as the 3%/3mm criteria. For the 2%/2mm criteria, AC can perfectly identify the MLC error of ± 2mm and the %DE of 3% to 4%. PD and LF can identify the MLC error of ± 1.2mm and the %DE of 2% to 3%. Conclusion: Different patient-specific quality assurance (PSQA) systems have different sensitivity and recognition abilities to MLC aperture errors. Institutions should formulate their own customized %GP limits based on their PSQA process through ROC or other methods.

Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC.

Background/purpose: To access the comparative dosimetric and radiobiological advantages of two methods of intensity-modulated radiation therapy (IMRT)-based hybrid radiotherapy planning for stage III nonsmall cell lung cancer (NSCLC). Methods: Two hybrid planning methods were respectively characterized by conventional fraction radiotherapy (CFRT) and stereotactic body radiotherapy (SBRT) and CFRT and simultaneous integrated boost (SIB) planning. All plans were retrospectively completed using the 2 methods for 20 patients with stage III NSCLC. CFRT and SBRT dose regimes 2 Gy × 30 f and 12.5 Gy × 4 f were, respectively, used for planning target volume of lymph node (PTVLN) and planning target volume of the primary tumor (PTVPT), while dose regimes 2 Gy × 26 f for PTVLN and sequential 2 Gy × 4 f for PTVLN combined with 12.5 Gy × 4 f for PTVPT were adopted for CFRT and SIB plans. SBRT and SIB EQD2 dose were calculated voxel by voxel, and then, respectively, superimposed with 30-fraction and 26-fraction CFRT plan dose to achieve biological equivalent dose (BED) dosimetric parameters of CFRT and SBRT and CFRT and SIB plans. Tumor control probability (TCP)/normal tissue complication probability (NTCP) was, respectively, calculated by equivalent uniform dose/Lyman–Kutcher–Burman models. BED plan parameters and TCP/NTCP were analyzed between 2 methods of hybrid planning. Primary tumor/lymph node (LN)/total TCP values were, respectively, evaluated as a function of the radiation dose needed to control 50% of tumor (TCD50) for 20 patients. Dosimetric errors were analyzed by nontransit electronic portal imaging device dosimetry measurement during hybrid plan delivery. Results: Statistically lower BED plan parameters of PTVLN D2 and homogeneity index resulted in slightly lower averaged LN/total TCP curves by CFRT and SIB planning. The gaps between Max and Min LN/total TCP curves were significantly closer for CFRT and SIB planning, which indicated better robustness of LN/total TCPs. A lower esophagus dose resulted in a lower esophagus NTCP by CFRT and SIB planning, which may be compromised by 1 week shorter overall treatment time by CFRT and SIB irradiation. Spinal cord Dmax was significantly reduced by CFRT and SIB plans. The dose verification results of the subplans involved in hybrid plans were acceptable, which showed that the 2 methods of hybrid planning could be delivered accurately in our center. Conclusion: CFRT and SIB plannings have more advantages on BED plan parameters and TCP/NTCP than CFRT and SBRT planning, and both methods of IMRT-based hybrid planning could be executed accurately for stage III NSCLC. The effectiveness of the results needs to be validated in the hybrid trial.

Deep Learning for Patient-Specific Quality Assurance: Predicting Gamma Passing Rates for IMRT Based on Delivery Fluence Informed by log Files.

Objectives: In this study, we propose a deep learning-based approach to predict Intensity-modulated radiation therapy (IMRT) quality assurance (QA) gamma passing rates using delivery fluence informed by log files. Methods: A total of 112 IMRT plans for chest cancers were planned and measured by portal dosimetry equipped on TrueBeam linac. The convolutional neural network (CNN) based learning model was trained using delivery fluence as inputs and gamma passing rates (GPRs) of 4 different criteria (3%/3 mm, 2%/3 mm, 3%/2 mm, and 2%/2 mm) as outputs. Model performance for both validation and test sets was assessed using mean absolute error (MAE), mean squared error (MSE), root MSE (RMSE), Spearman rank correlation coefficients (Sr), and Determination coefficient (R2) between the measured and predicted GPR values. Results: In the test set, the MAE of the prediction model were 0.402, 0.511, 1.724, and 2.530, the MSE were 0.640, 0.986, 6.654, and 9.508, the RMSE were 0.800, 0.993, 2.580, and 3.083, the Sr were 0.643, 0.684, 0.821, and 0.824 (P < .001) and the R2 were 0.4110, 0.4666, 0.6677, and 0.6769 for 3%/3 mm, 3%/2 mm, 2%/3 mm, and 2%/2 mm, respectively. The MAE and RMSE of the prediction model decreased with stricter gamma criteria while the Sr and R2 between measured and predicted GPR values increased. Conclusions: The CNN prediction model based on delivery fluence informed by log files could accurately predict IMRT QA passing rates for different gamma criteria. It could reduce QA workload and improve efficiency in pretreatment QA. Our results suggest that the CNN prediction model based on delivery fluence informed by log files may be a promising tool for the gamma evaluation of IMRT QA.

Feasibility Study of Stereotactic Radiosurgery Treatment of Glomus Jugulare Tumors via HyperArc VMAT.

This study aims to report on the clinical validation and feasibility of utilizing a novel fully automated treatment planning and delivery system, HyperArc VMAT stereotactic radiosurgery (SRS) for glomus jugulare tumors (GJT). Independent dose verification of the HyperArc module via the MD Anderson's SRS head phantom irradiation and credentialing results showed compliance with the SRS treatment requirements per IROC MD Anderson's standard. Following the Alliance clinical trial, AAPM, RTOG protocols, and QUANTEC requirements, utilizing selected three-partial arc geometry of HyperArc module on TrueBeam Linac with 6MV-FFF beam, GJT SRS plans were generated for nine previously treated Gamma Knife (GK) radiosurgery patients using advanced Acuros-based algorithm to account for tissue inhomogeneity corrections and frameless immobilization with Q-fix mask and Encompass device insert. HyperArc VMAT produced highly conformal SRS dose distributions to GJT, a steep dose gradient around the GJT, and spared adjacent critical organs including the spinal cord (< 3.0 Gy). Due to faster patient setup and less MLC modulation through the target (average beam-on time, 6.2 minutes), the HyperArc VMAT plan can deliver a single high-dose of 18 Gy to the GJT in less than 15 minutes overall treatment time, significantly improving patient comfort and clinic workflow. Pretreatment portal dosimetry quality assurance results and independent dose verification via Monte Carlo-based physics second check met our clinical SRS protocol's requirements for treatment. Due to the highly conformal dose distribution, rapid dose fall-off, excellent sparing of adjacent critical organs, and highly precise and accurate treatment, clinical implementation of frameless HyperArc VMAT for GJT patients who may not have access to nor tolerate frame-based GK SRS treatment are underway.

A Comparison between Portal Dosimetry and Mobius3D Results for Patient-Specific Quality Assurance in Radiotherapy

A Comparison between Portal Dosimetry and Mobius3D Results for Patient-Specific Quality Assurance in Radiotherapy

Radiation hardness of PantherPix hybrid pixel detector

Hybrid pixel detectors (HPD) are nowadays well known and widely used in fundamental research, e.g. in high energy physics experiments. Over the last decade, segmented semiconductor detectors have also found use in medicine. The total doses received by medical radiation detectors often reach a significant level (up to several hundreds of kGy per decade), especially in applications such as transmission portal in-vivo dosimetry. Such doses might affect detector properties. Therefore, it is necessary to evaluate their performance after absorbing a significant radiation dose. PantherPix is a novel 2D hybrid pixel detector which is designed specifically for use in radiation therapy. As was concluded in earlier studies, it is suitable for radiotherapy quality assurance (QA) and portal dosimetry. In this paper, the PantherPix radiation hardness is investigated using a 60Co source. The dependence on dose of the full depletion voltage, leakage current, detector power consumption and detector response are provided. The PantherPix radiation tolerance has been shown to be adequate for common cumulative doses delivered to radiation detectors in radiotherapy over several decades and its performance has been verified for doses up to 3000 kGy.

Comparison of sliding window and field-in-field techniques for tangential whole breast irradiation using the Halcyon and Synergy Agility systems

BackgroundTo implement a tangential treatment technique for whole breast irradiation using the Varian Halcyon and to compare it with Elekta Synergy Agility plans.MethodsFor 20 patients two comparable treatment plans with respect to dose coverage and normal tissue sparing were generated. Tangential field-in-field treatment plans (Pinnacle/Synergy) were replanned using the sliding window technique (Eclipse/Halcyon). Plan specific QA was performed using the portal Dosimetry and the ArcCHECK phantom. Imaging and treatment dose were evaluated for treatment delivery on both systems using a modified CIRS Phantom.ResultsThe mean number of monitor units for a fraction dose of 2.67 Gy was 515 MUs and 260 MUs for Halcyon and Synergy Agility plans, respectively. The homogeneity index and dose coverage were similar for both treatment units. The plan specific QA showed good agreement between measured and calculated plans. All Halcyon plans passed portal dosimetry QA (3%/2 mm) with 100% points passing and ArcCheck QA (3%/2 mm) with 99.5%. Measurement of the cumulated treatment and imaging dose with the CIRS phantom resulted in lower dose to the contralateral breast for the Halcyon plans.ConclusionsFor the Varian Halcyon a plan quality similar to the Elekta Synergy device was achieved. For the Halcyon plans the dose contribution from the treatment fields to the contralateral breast was even lower due to less interleaf transmission of the Halcyon MLC and a lower contribution of scattered dose from the collimator system.